Aligos Therapeutics (ALGS) Competitors $39.84 +1.49 (+3.89%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALGS vs. RNAC, GLUE, ESPR, TKNO, CDXC, ORGO, ZVRA, VERV, CRVS, and SIGAShould you be buying Aligos Therapeutics stock or one of its competitors? The main competitors of Aligos Therapeutics include Cartesian Therapeutics (RNAC), Monte Rosa Therapeutics (GLUE), Esperion Therapeutics (ESPR), Alpha Teknova (TKNO), ChromaDex (CDXC), Organogenesis (ORGO), Zevra Therapeutics (ZVRA), Verve Therapeutics (VERV), Corvus Pharmaceuticals (CRVS), and SIGA Technologies (SIGA). These companies are all part of the "pharmaceutical products" industry. Aligos Therapeutics vs. Cartesian Therapeutics Monte Rosa Therapeutics Esperion Therapeutics Alpha Teknova ChromaDex Organogenesis Zevra Therapeutics Verve Therapeutics Corvus Pharmaceuticals SIGA Technologies Aligos Therapeutics (NASDAQ:ALGS) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations. Does the MarketBeat Community believe in ALGS or RNAC? Cartesian Therapeutics received 4 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 93.94% of users gave Cartesian Therapeutics an outperform vote while only 65.85% of users gave Aligos Therapeutics an outperform vote. CompanyUnderperformOutperformAligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% Cartesian TherapeuticsOutperform Votes3193.94% Underperform Votes26.06% Is ALGS or RNAC more profitable? Cartesian Therapeutics has a net margin of -510.72% compared to Aligos Therapeutics' net margin of -1,283.19%. Cartesian Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aligos Therapeutics-1,283.19% -114.34% -64.58% Cartesian Therapeutics -510.72%N/A -6.03% Does the media favor ALGS or RNAC? In the previous week, Cartesian Therapeutics had 5 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Cartesian Therapeutics and 2 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.57 beat Cartesian Therapeutics' score of 0.32 indicating that Aligos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aligos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk & volatility, ALGS or RNAC? Aligos Therapeutics has a beta of 2.73, suggesting that its stock price is 173% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.59, suggesting that its stock price is 41% less volatile than the S&P 500. Which has higher earnings and valuation, ALGS or RNAC? Aligos Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAligos Therapeutics$6.00M23.84-$87.68M-$13.32-2.99Cartesian Therapeutics$47.94M10.08-$219.71M-$52.83-0.36 Do insiders & institutionals have more ownership in ALGS or RNAC? 60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 8.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate ALGS or RNAC? Aligos Therapeutics presently has a consensus target price of $75.00, suggesting a potential upside of 88.25%. Cartesian Therapeutics has a consensus target price of $42.86, suggesting a potential upside of 125.33%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryCartesian Therapeutics beats Aligos Therapeutics on 12 of the 18 factors compared between the two stocks. Ad Banyan Hill PublishingDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office... I put all the details together for you here — but please hurry. Get Aligos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALGS vs. The Competition Export to ExcelMetricAligos TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.94M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E Ratio-2.9946.7391.3417.19Price / Sales23.84411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book1.303.894.794.78Net Income-$87.68M-$42.21M$120.07M$225.60M7 Day Performance16.94%-2.14%-1.89%-1.24%1 Month Performance102.49%4.21%11.45%3.36%1 Year Performance127.98%18.40%30.61%16.58% Aligos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALGSAligos Therapeutics3.9799 of 5 stars$39.84+3.9%$75.00+88.3%+161.2%$142.94M$6.00M-2.9990News CoverageGap DownHigh Trading VolumeRNACCartesian Therapeutics2.2965 of 5 stars$19.21+2.8%$43.00+123.8%-6.3%$488.32M$26M-0.3537Analyst ForecastNews CoveragePositive NewsGap DownGLUEMonte Rosa Therapeutics1.9014 of 5 stars$7.65+1.2%$16.00+109.2%+28.3%$469.99M$14.98M-4.1390Analyst DowngradeNews CoverageESPREsperion Therapeutics3.9116 of 5 stars$2.38+5.8%$8.17+243.1%-3.5%$468.94M$295.45M-3.69240Analyst ForecastAnalyst RevisionNews CoverageTKNOAlpha Teknova0.4761 of 5 stars$8.79+9.5%$5.00-43.1%+124.1%$468.60M$36.68M-11.73240Gap UpCDXCChromaDex4.594 of 5 stars$6.13+0.2%$8.00+30.5%+283.9%$468.23M$91.67M620.00106Analyst DowngradeORGOOrganogenesis4.2211 of 5 stars$3.52+3.5%$5.33+51.5%-20.6%$466.68M$433.14M-56.67950ZVRAZevra Therapeutics2.915 of 5 stars$8.52+0.5%$21.00+146.5%+78.9%$454.76M$24.49M-4.3065Positive NewsVERVVerve Therapeutics1.9692 of 5 stars$5.36-6.1%$25.75+380.4%-57.7%$453.78M$11.76M-2.32110CRVSCorvus Pharmaceuticals2.2319 of 5 stars$7.00-5.1%$12.83+83.3%+219.9%$449.80MN/A-7.8030Options VolumeNews CoverageHigh Trading VolumeSIGASIGA Technologies1.6095 of 5 stars$6.29+1.8%N/A+4.6%$449.11M$139.92M5.1540Positive NewsGap Down Related Companies and Tools Related Companies Cartesian Therapeutics Competitors Monte Rosa Therapeutics Competitors Esperion Therapeutics Competitors Alpha Teknova Competitors ChromaDex Competitors Organogenesis Competitors Zevra Therapeutics Competitors Verve Therapeutics Competitors Corvus Pharmaceuticals Competitors SIGA Technologies Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALGS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALGS Stock Alerts